Heparina Panpharma

Heparina Panpharma is a pharmaceutical product that contains the active ingredient heparin sodium. It is supplied for intravenous, subcutaneous, and hemodialysis administration. Marketed in the European Union and available by prescription only, the preparation belongs to the anticoagulant drug class and is used to reduce the risk of abnormal blood clot formation. The product is manufactured by Panpharma and meets strict regulatory EU quality standards.

Heparina Panpharma is indicated for clinical situations where anticoagulation is required to prevent or treat clot formation. It is commonly employed in hospital settings for patients at risk of venous thromboembolism and during renal replacement therapy.

- Prevention of deep‑vein thrombosis and pulmonary embolism in surgical or immobilized patients. - Treatment of acute venous thromboembolism, including deep‑vein thrombosis and pulmonary embolism. - Anticoagulation for patients undergoing hemodialysis to maintain circuit patency. - Peri‑operative anticoagulation when rapid onset and short duration are required. - Bridging therapy for patients transitioning between oral anticoagulants and procedural interventions.

Adverse reactions to Heparina Panpharma vary in frequency and severity; they are categorized as common, typically mild, or serious, requiring medical attention.

Common: - Minor bleeding at injection sites or from mucous membranes. - Localized bruising or hematoma formation. - Transient elevation of liver enzymes without clinical symptoms. - Mild thrombocytopenia that resolves without intervention.

Serious: - Major hemorrhage affecting internal organs or central nervous system. - Heparin‑induced thrombocytopenia (HIT) with a rapid drop in platelet count. - Allergic reactions such as urticaria, angioedema, or anaphylaxis.

Before prescribing Heparina Panpharma, clinicians should evaluate patient‑specific factors and monitor for potential complications associated with anticoagulant therapy.

- Assess bleeding risk, including recent surgery, trauma, or active gastrointestinal bleeding. - Review history of heparin‑induced thrombocytopenia or hypersensitivity to heparin products. - Adjust dose in patients with renal impairment or those receiving concurrent anticoagulants. - Monitor platelet counts regularly during prolonged therapy to detect HIT early. - Use caution in pregnancy; benefits must outweigh potential fetal risks. - Evaluate liver function tests if prolonged treatment is anticipated.

Heparina Panpharma may interact with other medications that affect hemostasis or platelet function, altering its anticoagulant effect.

Avoid: - Concurrent use with other anticoagulants such as warfarin, direct oral anticoagulants, or low‑molecular‑weight heparins. - Combination with antiplatelet agents like aspirin, clopidogrel, or ticagrelor without dose adjustment.

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase bleeding risk. - Thrombolytic agents (e.g., alteplase) used during acute clot dissolution. - Certain antibiotics (e.g., quinolones) that may potentiate anticoagulant effects. - Herbal supplements such as ginkgo biloba or garlic that affect platelet aggregation.